CDKN2A and pheochromocytoma: For example, CDKN2A correlated with the most cancer (10/33), and its high expression correlated with worse outcome in adrenocortical carcinoma (ACC) (p < 0.001, HR = 1.844), COAD (p = 0.008, HR = 1.261), kidney chromophobe (KICH) (p = 0.019, HR = 1.958), KIRC (p < 0.001, HR = 1.634), LIHC (p = 0.003, HR = 1.248), pheochromocytoma and paraganglioma (PCPG) (p = 0.004, HR = 2.907), thyroid carcinoma (THCA) (p = 0.008, HR = 1.866), UCEC (p < 0.001, HR = 1.286), while predicted better outcome in HNSC (p = 0.004, HR = 0.905), mesothelioma (MESO) (p = 0.008, HR = 0.666).